Subtopic Deep Dive
JC Virus
Research Guide
What is JC Virus?
JC virus (JCV) is a polyomavirus that establishes asymptomatic primary infection in childhood, persists latently in kidneys, and reactivates in the brain causing progressive multifocal leukoencephalopathy (PML) under immunosuppression.
JCV prevalence reaches 50-80% in healthy adults, with viral DNA detectable in urine and blood (Egli et al., 2009, 767 citations). Reactivation occurs in transplant recipients and natalizumab-treated multiple sclerosis patients, leading to demyelinating CNS disease (Kleinschmidt-DeMasters and Tyler, 2005, 1068 citations). Over 20 key papers document its molecular epidemiology and pathogenesis since 1983.
Why It Matters
JCV reactivation causes PML, a fatal opportunistic infection in 5-10% of natalizumab-treated MS patients with anti-JCV antibodies, guiding risk stratification via antibody index testing (Plavina et al., 2014, 426 citations). In renal transplant recipients, JCV co-infections with BKV complicate immunosuppression management (Hirsch et al., 2002, 1205 citations). Understanding JCV latency in kidneys informs monitoring protocols to prevent CNS tropism shifts (Chesters et al., 1983, 531 citations; Major et al., 1992, 529 citations).
Key Research Challenges
Distinguishing BKV from JCV reactivation
Quantitative PCR assays detect both viruses in plasma, but JCV brain tropism emerges late, delaying PML diagnosis (Egli et al., 2009). Immunosuppression confounds viral load interpretation in transplants (Hirsch et al., 2002). Nested PCR confirms tissue persistence but lacks prognostic value (Chesters et al., 1983).
Predicting PML risk in MS therapy
Anti-JCV antibody index stratifies natalizumab PML risk, but thresholds vary by duration and prior immunosuppressants (Plavina et al., 2014). Host JCV genotype influences neurovirulence during reactivation (Major et al., 1992). Seroprevalence assays show 50% false negatives in low-risk groups (Kleinschmidt-DeMasters and Tyler, 2005).
Modeling JCV kidney-brain tropism shift
JCV persists in kidneys via archetype promoters, rearranging to neurotropic variants in PML brains (Major et al., 1992). Phylogenetic tracking reveals recombination events, but in vitro models fail to replicate immunosuppression triggers (Chesters et al., 1983). Evolutionary dynamics require full-genome sequencing absent in most studies.
Essential Papers
Prospective Study of Polyomavirus Type BK Replication and Nephropathy in Renal-Transplant Recipients
Hans H. Hirsch, Wendy A. Knowles, Michael Dickenmann et al. · 2002 · New England Journal of Medicine · 1.2K citations
BKV nephropathy in renal-transplant recipients represents a secondary infection associated with rejection and its treatment in most cases and could be monitored by measuring the viral load in plasma.
Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis
Bette K. Kleinschmidt‐DeMasters, Kenneth L. Tyler · 2005 · New England Journal of Medicine · 1.1K citations
A 46-year-old woman with relapsing-remitting multiple sclerosis died from progressive multifocal leukoencephalopathy (PML) after having received 37 doses of natalizumab (300 mg every four weeks) as...
Prevalence of Polyomavirus BK and JC Infection and Replication in 400 Healthy Blood Donors
Adrian Egli, Laura Infanti, Alexis Dumoulin et al. · 2009 · The Journal of Infectious Diseases · 767 citations
Our study provides important data about polyomavirus infection and replication in healthy, immunocompetent individuals. These data indicate significant differences between BKV and JCV with respect ...
Identification of a Novel Polyomavirus from Patients with Acute Respiratory Tract Infections
Anne M. Gaynor, Michael D. Nissen, David M. Whiley et al. · 2007 · PLoS Pathogens · 696 citations
We report the identification of a novel polyomavirus present in respiratory secretions from human patients with symptoms of acute respiratory tract infection. The virus was initially detected in a ...
Persistence of DNA Sequences of BK Virus and JC Virus in Normal Human Tissues and in Diseased Tissues
P. M. Chesters, John Heritage, Dennis J. McCance · 1983 · The Journal of Infectious Diseases · 531 citations
Available evidence suggests that BK virus (BKV) and JC virus (JCV) persist in the kidneys of healthy individuals after primary infection and may reactivate when the host's immune response is impair...
Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain
Eugene O. Major, Kei Amemiya, Carlo Tornatore et al. · 1992 · Clinical Microbiology Reviews · 529 citations
Studies of the pathogenesis and molecular biology of JC virus infection over the last two decades have significantly changed our understanding of progressive multifocal leukoencephalopathy, which c...
BK Polyomavirus in Solid Organ Transplantation
Hans H. Hirsch, Parmjeet Randhawa · 2013 · American Journal of Transplantation · 519 citations
Reading Guide
Foundational Papers
Start with Chesters et al. (1983, 531 citations) for kidney persistence evidence, then Major et al. (1992, 529 citations) for PML molecular pathogenesis, followed by Egli et al. (2009, 767 citations) for prevalence baselines.
Recent Advances
Plavina et al. (2014, 426 citations) on anti-JCV index for PML risk; Hirsch and Randhawa (2013, 519 citations) on polyomavirus in transplants.
Core Methods
Quantitative PCR for viral load (Hirsch et al., 2002); nested PCR for tissue detection (Chesters et al., 1983); antibody index ELISA (Plavina et al., 2014); promoter sequencing for tropism (Major et al., 1992).
How PapersFlow Helps You Research JC Virus
Discover & Search
Research Agent uses searchPapers('JC virus PML natalizumab risk') to retrieve Plavina et al. (2014), then citationGraph reveals 426 citing papers on antibody stratification, while findSimilarPapers expands to Hirsch et al. (2002) for transplant contexts.
Analyze & Verify
Analysis Agent applies readPaperContent on Egli et al. (2009) to extract JCV prevalence data (58% seropositivity), verifyResponse with CoVe cross-checks against Kleinschmidt-DeMasters (2005) for PML case confirmation, and runPythonAnalysis computes meta-analysis odds ratios from 5 papers using pandas for reactivation rates.
Synthesize & Write
Synthesis Agent detects gaps in JCV genotype-PML links post-Major et al. (1992), flags contradictions in tropism models; Writing Agent uses latexEditText for manuscript sections, latexSyncCitations integrates 10 papers, and latexCompile generates PML pathogenesis review with exportMermaid for virus lifecycle diagrams.
Use Cases
"Calculate JCV vs BKV viral load ratios in transplant urine from Egli 2009 and Hirsch 2002"
Research Agent → searchPapers → Analysis Agent → readPaperContent + runPythonAnalysis (pandas loads tables, computes log10 ratios, matplotlib plots) → CSV export of 95% CIs for clinical thresholds.
"Draft LaTeX review on JCV PML risk factors with natalizumab cases"
Synthesis Agent → gap detection → Writing Agent → latexEditText (imports Kleinschmidt-DeMasters 2005 abstract) → latexSyncCitations (adds Plavina 2014) → latexCompile → PDF with figure captions.
"Find code for JCV genome phylogenetics from polyomavirus papers"
Research Agent → paperExtractUrls (scans Major 1992) → paperFindGithubRepo → Code Discovery → githubRepoInspect (phylogeny scripts) → runPythonAnalysis tests on JCV sequences.
Automated Workflows
Deep Research workflow scans 50+ polyomavirus papers via searchPapers, structures JCV latency report with GRADE grading on Egli (2009) evidence. DeepScan's 7-step chain verifies PML tropism claims in Major (1992) using CoVe checkpoints and runPythonAnalysis for sequence alignments. Theorizer generates hypotheses on JCV recombination from citationGraph of Chesters (1983) descendants.
Frequently Asked Questions
What defines JC virus infection?
JC virus causes primary childhood infection, persists in kidneys, and reactivates as PML in immunosuppressed adults (Egli et al., 2009; Chesters et al., 1983).
What methods detect JCV reactivation?
Quantitative PCR measures JCV DNA in plasma/urine; anti-JCV antibody index predicts PML risk in natalizumab users (Plavina et al., 2014; Hirsch et al., 2002).
What are key papers on JCV?
Hirsch et al. (2002, 1205 citations) on transplants; Kleinschmidt-DeMasters and Tyler (2005, 1068 citations) on natalizumab PML; Major et al. (1992, 529 citations) on pathogenesis.
What open problems exist in JCV research?
Predicting neurotropic shift from kidney latency; genotype-specific PML risk; in vitro reactivation models under immunosuppression (Major et al., 1992).
Research Polyomavirus and related diseases with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching JC Virus with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Polyomavirus and related diseases Research Guide